{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T12:25:06Z","timestamp":1764937506344,"version":"3.41.2"},"reference-count":129,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>In the field of autoimmune and inflammatory disorders, different approaches were applied to provide information regarding disease activity, comorbidities, epidemiological reports and risk factors. However, no previous studies had thoroughly analyzed the research trend in the field, and the bibliometric analysis focusing on pemphigoid diseases was available. The objective of the current study was to evaluate the current research trend in the field.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A search has been conducted for the Web of Science database based on various subcategories of pemphigoid diseases. Detailed information including articles\u2019 publication types, Author information, citation, and publication information was attained for further analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Within the 6,995 studies, the top 100 most-cited articles were extracted for analysis. Among the top 100 studies, 70% of the studies focused on bullous pemphigoid. More than 60% of the top 100 studies were studies with original data. Furthermore, 30% of the studies were guidelines and narrative reviews. For the issues primarily focused on, most of the high-impact studies described the molecular mechanism of pemphigoid diseases (26%), managements (19%), risk factors of pemphigoid diseases (17%). Additionally, some other studies provided general review or discussed about the issue of epidemiology, diagnosis\/definition, comorbidities and clinical characteristics of pemphigoid diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This comprehensive bibliographic study of pemphigoid diseases provided an overview of current research focuses in the field. Topics such as disease management, molecular mechanism of pathogenesis, and drug-inducing pemphigoid diseases were highly mentioned in the most-cited studies. For researchers and clinicians, the researching trend and study focus in the top-100 cited studies could serve as a potential reference for future investigation and patient management.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2022.1088083","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T08:39:09Z","timestamp":1673253549000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Researching trends in pemphigoid diseases: A bibliometric study of the top 100 most cited publications"],"prefix":"10.3389","volume":"9","author":[{"given":"Shih-Cheng","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsu-Man","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chien-Ying","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Chin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Jun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo-Yan","family":"Gau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1590\/abd1806-4841.20164935","article-title":"Quality of life, depression, anxiety and loneliness in patients with bullous pemphigoid. A case control study.","volume":"91","author":"Kouris","year":"2016","journal-title":"An Bras Dermatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases.","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet."},{"key":"B3","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/bjd.20743","article-title":"The global incidence of bullous pemphigoid: a systematic review and meta-analysis.","volume":"186","author":"Persson","year":"2022","journal-title":"Br J Dermatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1093\/eurjpc\/zwab176","article-title":"Tramadol use increases mortality and risk of major adverse cardiovascular events in rheumatoid arthritis patients: evidence from a population-based cohort study.","volume":"29","author":"Gau","year":"2022","journal-title":"Eur J Prev Cardiol."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.840106","article-title":"Bidirectional association between psoriasis and nonalcoholic fatty liver disease: real-world evidence from two longitudinal cohort studies.","volume":"13","author":"Gau","year":"2022","journal-title":"Front Immunol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00392","article-title":"Patients with rheumatoid arthritis increased risk of developing osteoarthritis: a nationwide population-based cohort study in Taiwan.","volume":"7","author":"Lee","year":"2020","journal-title":"Front Med (Lausanne)."},{"key":"B7","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1067\/mjd.2001.116337","article-title":"Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment.","volume":"45","author":"Ahmed","year":"2001","journal-title":"J Am Acad Dermatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00403-014-1531-1","article-title":"Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid.","volume":"307","author":"Alpsoy","year":"2015","journal-title":"Arch Dermatol Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s12016-017-8633-4","article-title":"Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features, diagnosis, and management.","volume":"54","author":"Amber","year":"2018","journal-title":"Clin Rev Allergy Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1111\/j.1600-0625.2011.01378.x","article-title":"Lesional Th17 cells and regulatory T cells in bullous pemphigoid.","volume":"20","author":"Arakawa","year":"2011","journal-title":"Exp Dermatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/jid.2010.301","article-title":"Risk factors for bullous pemphigoid in the elderly: a prospective case-control study.","volume":"131","author":"Bastuji-Garin","year":"2011","journal-title":"J Invest Dermatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1001\/archderm.143.12.1536","article-title":"A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid.","volume":"143","author":"Beissert","year":"2007","journal-title":"Arch Dermatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/bjd.14601","article-title":"Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French pharmacovigilance database.","volume":"175","author":"Bene","year":"2016","journal-title":"Br J Dermatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jaad.2017.12.038","article-title":"Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: retrospective multicenter case-control study from France and Switzerland.","volume":"78","author":"Benzaquen","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40257-017-0264-2","article-title":"Bullous pemphigoid: a review of its diagnosis, associations and treatment.","volume":"18","author":"Bernard","year":"2017","journal-title":"Am J Clin Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1001\/archdermatol.2009.53","article-title":"Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study.","volume":"145","author":"Bernard","year":"2009","journal-title":"Arch Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1610-0387.2008.06976.x","article-title":"Prospective analysis of the incidence of autoimmune bullous disorders in lower franconia, Germany.","volume":"7","author":"Bertram","year":"2009","journal-title":"J Dtsch Dermatol Ges."},{"key":"B18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaad.2014.02.030","article-title":"Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009.","volume":"71","author":"Brick","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/CMR.0000000000000155","article-title":"A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab.","volume":"25","author":"Carlos","year":"2015","journal-title":"Melanoma Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/archderm.138.3.370","article-title":"The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators.","volume":"138","author":"Chan","year":"2002","journal-title":"Arch Dermatol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1001\/archdermatol.2011.23","article-title":"Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients.","volume":"147","author":"Charneux","year":"2011","journal-title":"Arch Dermatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/j.1365-2133.2011.10386.x","article-title":"Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study.","volume":"165","author":"Chen","year":"2011","journal-title":"Br J Dermatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.det.2009.10.011","article-title":"Type VII collagen: the anchoring fibril protein at fault in dystrophic epidermolysis bullosa.","volume":"28","author":"Chung","year":"2010","journal-title":"Dermatol Clin."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1111\/j.0022-202X.2004.22504.x","article-title":"Mortality rate of bullous pemphigoid in a US medical center.","volume":"122","author":"Colbert","year":"2004","journal-title":"J Invest Dermatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000106574","article-title":"Neurological disorders in patients with bullous pemphigoid.","volume":"215","author":"Cordel","year":"2007","journal-title":"Dermatology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1073\/pnas.0809230106","article-title":"Anti-laminin gamma-1 pemphigoid.","volume":"106","author":"Dainichi","year":"2009","journal-title":"Proc Natl Acad Sci USA."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.clindermatol.2011.03.005","article-title":"Bullous pemphigoid: from the clinic to the bench.","volume":"30","author":"Di Zenzo","year":"2012","journal-title":"Clin Dermatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1046\/j.0022-202X.2003.22126.x","article-title":"Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients.","volume":"122","author":"Di Zenzo","year":"2004","journal-title":"J Invest Dermatol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1038\/jid.2011.180","article-title":"Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study.","volume":"131","author":"Di Zenzo","year":"2011","journal-title":"J Invest Dermatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.clim.2008.04.012","article-title":"Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid.","volume":"128","author":"Di Zenzo","year":"2008","journal-title":"Clin Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1046\/j.1523-1747.2003.12146.x","article-title":"Identification of a potential effector function for IgE autoantibodies in the organ-specific autoimmune disease bullous pemphigoid.","volume":"120","author":"Dimson","year":"2003","journal-title":"J Invest Dermatol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1016\/S0140-6736(00)04971-0","article-title":"Anti-epiligrin cicatricial pemphigoid and relative risk for cancer.","volume":"357","author":"Egan","year":"2001","journal-title":"Lancet."},{"key":"B33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/01.md.0000076003.64510.00","article-title":"Anti-epiligrin cicatricial pemphigoid: clinical findings, immunopathogenesis, and significant associations.","volume":"82","author":"Egan","year":"2003","journal-title":"Medicine (Baltimore)."},{"key":"B34","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaci.2008.11.035","article-title":"Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab.","volume":"123","author":"Fairley","year":"2009","journal-title":"J Allergy Clin Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/bjd.13717","article-title":"Management of bullous pemphigoid: the European dermatology forum consensus in collaboration with the European academy of dermatology and venereology.","volume":"172","author":"Feliciani","year":"2015","journal-title":"Br J Dermatol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.clindermatol.2011.03.008","article-title":"Linear immunoglobulin A bullous dermatosis.","volume":"30","author":"Fortuna","year":"2012","journal-title":"Clin Dermatol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.ophtha.2009.09.049","article-title":"Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report.","volume":"117","author":"Foster","year":"2010","journal-title":"Ophthalmology."},{"key":"B38","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1365-2133.2005.06662.x","article-title":"Annual incidence and mortality of bullous pemphigoid in the grampian region of North-East Scotland.","volume":"153","author":"Gudi","year":"2005","journal-title":"Br J Dermatol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/s0738-081x(00)00185-1","article-title":"Linear IgA bullous dermatosis.","volume":"19","author":"Guide","year":"2001","journal-title":"Clin Dermatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.clindermatol.2011.03.011","article-title":"Epidermolysis bullosa acquisita.","volume":"30","author":"Gupta","year":"2012","journal-title":"Clin Dermatol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1146\/annurev-pathol-012615-044313","article-title":"Mechanisms of disease: pemphigus and bullous pemphigoid.","volume":"11","author":"Hammers","year":"2016","journal-title":"Annu Rev Pathol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1172\/JCI28547","article-title":"T cell control in autoimmune bullous skin disorders.","volume":"116","author":"Hertl","year":"2006","journal-title":"J Clin Invest."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1046\/j.1523-1747.2002.19529.x","article-title":"Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain.","volume":"119","author":"Hofmann","year":"2002","journal-title":"J Invest Dermatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1016\/j.jid.2016.07.013","article-title":"Prevalence and age distribution of pemphigus and pemphigoid diseases in Germany.","volume":"136","author":"Hubner","year":"2016","journal-title":"J Invest Dermatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/jid.2008.305","article-title":"IgG from patients with bullous pemphigoid depletes cultured keratinocytes of the 180-kDa bullous pemphigoid antigen (type XVII collagen) and weakens cell attachment.","volume":"129","author":"Iwata","year":"2009","journal-title":"J Invest Dermatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/archdermatol.2007.9","article-title":"Correlation of IgE autoantibody to BP180 with a severe form of bullous pemphigoid.","volume":"144","author":"Iwata","year":"2008","journal-title":"Arch Dermatol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/j.jid.2016.06.622","article-title":"Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid.","volume":"136","author":"Izumi","year":"2016","journal-title":"J Invest Dermatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1684\/ejd.2010.0805","article-title":"Bullous pemphigoid and internal diseases - a case-control study.","volume":"20","author":"Jedlickova","year":"2010","journal-title":"Eur J Dermatol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in France.","volume":"132","author":"Joly","year":"2012","journal-title":"J Invest Dermatol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1001\/archderm.141.6.691","article-title":"Prediction of survival for patients with bullous pemphigoid: a prospective study.","volume":"141","author":"Joly","year":"2005","journal-title":"Arch Dermatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1038\/jid.2008.412","article-title":"A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study.","volume":"129","author":"Joly","year":"2009","journal-title":"J Invest Dermatol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid.","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1111\/cup.12717","article-title":"Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions.","volume":"43","author":"Jour","year":"2016","journal-title":"J Cutan Pathol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jaad.2010.07.032","article-title":"Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients.","volume":"65","author":"Kasperkiewicz","year":"2011","journal-title":"J Am Acad Dermatol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12016-007-0030-y","article-title":"The pathophysiology of bullous pemphigoid.","volume":"33","author":"Kasperkiewicz","year":"2007","journal-title":"Clin Rev Allergy Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.autrev.2014.01.011","article-title":"Diagnosis and classification of pemphigus and bullous pemphigoid.","volume":"13","author":"Kershenovich","year":"2014","journal-title":"Autoimmun Rev."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002292.pub3","article-title":"Interventions for bullous pemphigoid.","volume":"2010","author":"Kirtschig","year":"2010","journal-title":"Cochrane Database Syst Rev."},{"key":"B58","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/j.1610-0387.2011.07793.x","article-title":"Autoimmune bullous skin diseases. Part 1: clinical manifestations.","volume":"9","author":"Kneisel","year":"2011","journal-title":"J Dtsch Dermatol Ges."},{"key":"B59","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/s0923-1811(02)00109-3","article-title":"BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid.","volume":"30","author":"Kobayashi","year":"2002","journal-title":"J Dermatol Sci."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1001\/jamadermatol.2018.2352","article-title":"Association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors in patients with diabetes: estimating the risk of the new agents and characterizing the patients.","volume":"154","author":"Kridin","year":"2018","journal-title":"JAMA Dermatol."},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00220","article-title":"The growing incidence of bullous pemphigoid: overview and potential explanations.","volume":"5","author":"Kridin","year":"2018","journal-title":"Front Med (Lausanne)."},{"key":"B62","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/jid.2010.357","article-title":"The relationship between neurological disease and bullous pemphigoid: a population-based case-control study.","volume":"131","author":"Langan","year":"2011","journal-title":"J Invest Dermatol."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris\u2013incidence and mortality in the UK: population based cohort study.","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1038\/jid.2014.263","article-title":"Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid.","volume":"134","author":"Le Jan","year":"2014","journal-title":"J Invest Dermatol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/archdermatol.2011.54","article-title":"Rituximab for patients with refractory mucous membrane pemphigoid.","volume":"147","author":"Le Roux-Villet","year":"2011","journal-title":"Arch Dermatol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/2013.jamadermatol.376","article-title":"The associations between bullous pemphigoid and drug use: a UK case-control study.","volume":"149","author":"Lloyd-Lavery","year":"2013","journal-title":"JAMA Dermatol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.clindermatol.2013.01.006","article-title":"Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies.","volume":"31","author":"Lo Schiavo","year":"2013","journal-title":"Clin Dermatol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/ijd.13984","article-title":"A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors.","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/j.1365-2133.2009.09300.x","article-title":"Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study.","volume":"161","author":"Marazza","year":"2009","journal-title":"Br J Dermatol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1111\/j.1582-4934.2007.00033.x","article-title":"Immunopathology and molecular diagnosis of autoimmune bullous diseases.","volume":"11","author":"Mihai","year":"2007","journal-title":"J Cell Mol Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts.","volume":"66","author":"Murrell","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jaad.2014.08.024","article-title":"Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts.","volume":"72","author":"Murrell","year":"2015","journal-title":"J Am Acad Dermatol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1.","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res."},{"key":"B74","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jdermsci.2013.12.001","article-title":"Update on the pathogenesis of bullous pemphigoid: an autoantibody-mediated blistering disease targeting collagen XVII.","volume":"73","author":"Nishie","year":"2014","journal-title":"J Dermatol Sci."},{"key":"B75","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.1365-2133.2005.06998.x","article-title":"Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity.","volume":"154","author":"Oyama","year":"2006","journal-title":"Br J Dermatol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jaad.2008.07.022","article-title":"Mortality of bullous pemphigoid: an evaluation of 223 patients and comparison with the mortality in the general population in the United States.","volume":"59","author":"Parker","year":"2008","journal-title":"J Am Acad Dermatol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1001\/archderm.138.7.903","article-title":"Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age.","volume":"138","author":"Rzany","year":"2002","journal-title":"Arch Dermatol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jdermsci.2011.03.003","article-title":"Development of NC1 and NC2 domains of type VII collagen ELISA for the diagnosis and analysis of the time course of epidermolysis bullosa acquisita patients.","volume":"62","author":"Saleh","year":"2011","journal-title":"J Dermatol Sci."},{"key":"B79","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jaad.2013.07.009","article-title":"Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid.","volume":"69","author":"Sardy","year":"2013","journal-title":"J Am Acad Dermatol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"253.e","DOI":"10.1016\/j.ophtha.2007.04.027","article-title":"Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes.","volume":"115","author":"Saw","year":"2008","journal-title":"Ophthalmology."},{"key":"B81","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/ddg.12612","article-title":"S2k guideline for the diagnosis of pemphigus vulgaris\/foliaceus and bullous pemphigoid.","volume":"13","author":"Schmidt","year":"2015","journal-title":"J Dtsch Dermatol Ges."},{"key":"B82","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1365-2230.2006.02151.x","article-title":"Rituximab in refractory autoimmune bullous diseases.","volume":"31","author":"Schmidt","year":"2006","journal-title":"Clin Exp Dermatol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1365-2133.2006.07646.x","article-title":"Rituximab in autoimmune bullous diseases: mixed responses and adverse effects.","volume":"156","author":"Schmidt","year":"2007","journal-title":"Br J Dermatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1046\/j.1365-2133.2001.04471.x","article-title":"Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180.","volume":"145","author":"Schmidt","year":"2001","journal-title":"Br J Dermatol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.autrev.2010.08.007","article-title":"Modern diagnosis of autoimmune blistering skin diseases.","volume":"10","author":"Schmidt","year":"2010","journal-title":"Autoimmun Rev."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy.","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1111\/j.1600-0625.2007.00592.x","article-title":"Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies.","volume":"16","author":"Sitaru","year":"2007","journal-title":"Exp Dermatol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/s0002-9440(10)64182-x","article-title":"Autoantibodies to type VII collagen mediate Fcgamma-dependent neutrophil activation and induce dermal-epidermal separation in cryosections of human skin.","volume":"161","author":"Sitaru","year":"2002","journal-title":"Am J Pathol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1468-3083.2011.04062.x","article-title":"Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin.","volume":"26","author":"Skandalis","year":"2012","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/jdv.12366","article-title":"Drug-induced pemphigoid: a review of the literature.","volume":"28","author":"Stavropoulos","year":"2014","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1001\/archdermatol.2010.322","article-title":"The association of bullous pemphigoid with cerebrovascular disease and dementia: a case-control study.","volume":"146","author":"Taghipour","year":"2010","journal-title":"Arch Dermatol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1111\/j.0022-202X.2004.22603.x","article-title":"BP230- and BP180-specific auto-antibodies in bullous pemphigoid.","volume":"122","author":"Thoma-Uszynski","year":"2004","journal-title":"J Invest Dermatol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.4049\/jimmunol.176.3.2015","article-title":"Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230.","volume":"176","author":"Thoma-Uszynski","year":"2006","journal-title":"J Immunol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ophtha.2003.03.001","article-title":"Mucous membrane pemphigoid and pseudopemphigoid.","volume":"111","author":"Thorne","year":"2004","journal-title":"Ophthalmology."},{"key":"B95","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jdermsci.2004.10.007","article-title":"Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid.","volume":"37","author":"Tsuji-Abe","year":"2005","journal-title":"J Dermatol Sci."},{"key":"B96","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamadermatol.2016.3357","article-title":"Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity.","volume":"153","author":"van Beek","year":"2017","journal-title":"JAMA Dermatol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.jid.2018.01.027","article-title":"Vildagliptin significantly increases the risk of bullous pemphigoid: a finnish nationwide registry study.","volume":"138","author":"Varpuluoma","year":"2018","journal-title":"J Invest Dermatol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1111\/bjd.12072","article-title":"British association of dermatologists\u2019 guidelines for the management of bullous pemphigoid 2012.","volume":"167","author":"Venning","year":"2012","journal-title":"Br J Dermatol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1046\/j.0022-202x.2001.01521.x","article-title":"Respective contribution of neutrophil elastase and matrix metalloproteinase 9 in the degradation of BP180 (type XVII collagen) in human bullous pemphigoid.","volume":"117","author":"Verraes","year":"2001","journal-title":"J Invest Dermatol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1111\/j.1365-2133.2004.06006.x","article-title":"U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases.","volume":"151","author":"Vodegel","year":"2004","journal-title":"Br J Dermatol."},{"key":"B101","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jaad.2007.08.010","article-title":"Bullous pemphigoid in infancy: clinical and epidemiologic characteristics.","volume":"58","author":"Waisbourd-Zinman","year":"2008","journal-title":"J Am Acad Dermatol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial.","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet."},{"key":"B103","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1046\/j.1365-2133.2002.04835.x","article-title":"Guidelines for the management of bullous pemphigoid.","volume":"147","author":"Wojnarowska","year":"2002","journal-title":"Br J Dermatol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jdermsci.2005.11.002","article-title":"Enzyme-linked immunosorbent assay using bacterial recombinant proteins of human BP230 as a diagnostic tool for bullous pemphigoid.","volume":"41","author":"Yoshida","year":"2006","journal-title":"J Dermatol Sci."},{"key":"B105","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","article-title":"Omalizumab therapy for bullous pemphigoid.","volume":"71","author":"Yu","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1590\/abd1806-4841.2019940207","article-title":"Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian society of dermatology.","author":"Santi","year":"2019","journal-title":"An Bras Dermatol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1111\/1346-8138.15111","article-title":"Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita).","volume":"46","author":"Ujiie","year":"2019","journal-title":"J Dermatol."},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01506","article-title":"New insights into the pathogenesis of bullous pemphigoid: 2019 update.","volume":"10","author":"Genovese","year":"2019","journal-title":"Front Immunol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series.","volume":"83","author":"Abdat","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.928621","article-title":"Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review.","volume":"13","author":"Cao","year":"2022","journal-title":"Front Immunol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"e539","DOI":"10.1111\/jdv.17999","article-title":"Efficacy and safety of methotrexate, omalizumab and dupilumab for bullous pemphigoid in patients resistant or contraindicated to oral steroids. A monocentric real-life study.","volume":"36","author":"Velin","year":"2022","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jdcr.2022.07.013","article-title":"Successful treatment of recalcitrant mucous membrane pemphigoid with multisystem involvement with baricitinib and methotrexate.","volume":"27","author":"Burningham","year":"2022","journal-title":"JAAD Case Rep."},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6716419","article-title":"Expression of the JAK\/STAT signaling pathway in bullous pemphigoid and dermatitis herpetiformis.","volume":"2017","author":"Juczynska","year":"2017","journal-title":"Mediators Inflamm."},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00362","article-title":"Epidermolysis bullosa acquisita: the 2019 update.","volume":"5","author":"Koga","year":"2018","journal-title":"Front Med (Lausanne)."},{"key":"B115","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40257-018-0401-6","article-title":"Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature.","volume":"20","author":"Kremer","year":"2019","journal-title":"Am J Clin Dermatol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1001\/jamadermatol.2018.4556","article-title":"Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes.","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1590\/abd1806-4841.20199007","article-title":"Bullous pemphigoid.","volume":"94","author":"Miyamoto","year":"2019","journal-title":"An Bras Dermatol."},{"key":"B118","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jid.2018.10.045","article-title":"Higher frequency of dipeptidyl peptidase-4 inhibitor intake in bullous pemphigoid patients than in the French general population.","volume":"139","author":"Plaquevent","year":"2019","journal-title":"J Invest Dermatol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1016\/j.jaci.2020.02.013","article-title":"Autoimmune bullous skin diseases, pemphigus and pemphigoid.","volume":"145","author":"Egami","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jaad.2019.07.060","article-title":"Pathophysiologic mechanisms of itch in bullous pemphigoid.","volume":"83","author":"Hashimoto","year":"2020","journal-title":"J Am Acad Dermatol."},{"key":"B121","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jamadermatol.2020.1587","article-title":"Association between medication use and bullous pemphigoid: a systematic review and meta-analysis.","volume":"156","author":"Liu","year":"2020","journal-title":"JAMA Dermatol."},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3457","article-title":"A systematic review of drug-induced pemphigoid.","volume":"100","author":"Verheyden","year":"2020","journal-title":"Acta Derm Venereol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1111\/jdv.17472","article-title":"The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?","volume":"35","author":"Damiani","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"e412","DOI":"10.1111\/jdv.17207","article-title":"Updated international expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic.","volume":"35","author":"Kasperkiewicz","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jaad.2018.09.048","article-title":"Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid: a systematic review and meta-analysis.","volume":"85","author":"Kridin","year":"2021","journal-title":"J Am Acad Dermatol."},{"key":"B126","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/bjd.19022","article-title":"Incidence, prevalence and mortality of bullous pemphigoid in England 1998-2017: a population-based cohort study.","volume":"184","author":"Persson","year":"2021","journal-title":"Br J Dermatol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1111\/jdv.17395","article-title":"European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European academy of dermatology and venereology - Part II.","volume":"35","author":"Schmidt","year":"2021","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.995873","article-title":"Top 100 most-cited publications in hidradenitis suppurativa: an updated bibliometric analysis.","volume":"9","author":"Teng","year":"2022","journal-title":"Front Med (Lausanne)."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/ijd.14261","article-title":"The 100 top-cited publications in psoriatic arthritis: a bibliometric analysis.","volume":"58","author":"Berlinberg","year":"2019","journal-title":"Int J Dermatol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1088083\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T08:39:20Z","timestamp":1673253560000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.1088083\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":129,"alternative-id":["10.3389\/fmed.2022.1088083"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.1088083","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"article-number":"1088083"}}